Wednesday broker round-up
8th Aug 2012 09:57
AstraZeneca: Jefferies raises target from 2,975p to 3,100p, hold rating kept. Avon Rubber: Investec reiterates hold rating and 315p target. BTG: Jefferies maintains hold rating and 410p target. Cobham: Jefferies reiterates buy recommendation and 230p target; Investec keeps sell rating and 200p ta
Read moreASOS director reduces stake
25th Jun 2012 13:18
Robert Bready, the Product Director of ASOS, the online clothes retailer, has slimmed down his stake in the firm with the sale of 44,299 shares. The transaction, which was carried out on Monday, earned Bready £724,289 and reduced his holding to 143,125 ordinary shares, equal to 0.18% of the total
Read moreHikma boss makes a fair few pennies from share sale
21st Jun 2012 16:24
Said Darwazah, the Chief Executive Officer of Hikma Pharmaceuticals, the FTSE 250 multinational pharmaceutical group, has pocketed over one million pounds through the sale of company shares last week. Darwazah sold 195,447 shares at 649p each on June 15th for a total of £1,268,451, the company reve
Read moreHikma reiterates guidance despite generics hiccups
17th May 2012 09:48
Things appear to be proceeding to plan at Hikma Pharmaceuticals as it has reiterated its revenue growth guidance for 2012, despite a few setbacks in its generic drugs business. "We are making good progress towards delivering our targets for this year and surpassing the important milestone of $1bn i
Read moreLondon close: Stocks snap four-day winning streak
30th Apr 2012 16:30
- Chicago PMI, US consumer spending disappoints - Spain joins the UK in recession - Global stock markets in the red With economic data missing expectations Stateside and Spain continuing to dampen the outlook for the Eurozone economy, London's FTSE 100 index slumped on Monday, snapping a four-day w
Read moreFTSE 250 movers: Essar rebounds while Aquarius plummets
30th Apr 2012 15:37
Essar Energy saw its share price jump by nearly a tenth today with analysts pinning the stock's performance to a simple correction following its recent slump. Even after taking today's rise into account, the stock is still worth less than half off its six-month high of 312.1p. Platinum producer Aqu
Read moreMonday broker round-up
30th Apr 2012 08:29
Anglo American: AlphaValue downgrades from neutral to reduce, target cut from 7,115p to 6,970p. AstraZeneca: Jefferies upgrades from hold to buy, target cut from 3,050p to 2,975p; JP Morgan Cazenove upgrades from underweight to neutral, target hiked from 2,800p to 3,050p. British Sky Broadcasting:
Read moreBroker tips: Burberry, M and S, Hikma
17th Apr 2012 14:27
Merchant Securities has cut its rating for luxury brand Burberry from buy to hold on valuation grounds, but has maintained its positive stance on the group. "We continue to believe that Burberry is a beneficiary of growing demand from global luxury travellers, especially in Asia, Middle East and Ru
Read moreBroker snap: UBS upgrades Hikma after recent falls
17th Apr 2012 10:47
UBS has upgraded its rating for pharmaceuticals group Hikma from neutral to buy, leaving its 755p target price unchanged, following the sell-off since the firm's full-year results last month. The broker sees a 10% and 6% downside risk to 2012 and 2013 earnings per share estimates - "we believe cons
Read moreTuesday broker round-up - UPDATE
17th Apr 2012 08:36
BHP Billiton: Jefferies reiterates buy rating and 2,500p target. Burberry: Merchant Securities downgrades from buy to hold; Investec maintains buy recommendation and 1,690p target. Dairy Crest: Numis upgrades from add to buy. Daily Mail & General Trust: Investec maintains buy rating and 578p targ
Read moreFriday broker round-up - UPDATE
16th Mar 2012 10:27
4imprint: Peel Hunt keeps buy rating and 345p target. Aegis: Nomura reiterates buy rating and 210p target; HB Markets upgrades from sell to hold. Antofagasta: Jefferies keeps hold and 1,214p target. Bunzl: Goldman Sachs downgrades from neutral to sell, target lifted from 940p to 988p. Diageo: Je
Read moreExceptional charges dent Hikma's profits
14th Mar 2012 08:09
Drugs developer Hikma Pharmaceuticals kept up its track record of doubling revenues every four years, but it will be less pleased with the slide in profits in 2011 as exceptional charges increased. Profits before tax fell from $120.98m to $93.89m, after operating expenses soared. Group operating ex
Read moreMonday broker round-up - UPDATE
14th Nov 2011 09:19
Barclays: Goldman Sachs cuts to sell from neutral. BG Group: Evolution Securities keeps buy recommendation and 1,800p target. BG Group: Nomura maintains buy and 1,750p target. ITV: Peel Hunt retains buy and 73p target. ITV: Investec maintains hold rating and 55p target. Cairn Energy: UBS cuts
Read moreHikma non execs buy big stakes
18th Oct 2011 15:34
Two non-executive directors at Hikma Pharmaceuticals have upped their stakes in the Arab world-focused pharmaceutical company. Ronald Goode took 8,000 shares at 633p a time, lifting his stake to 22,700 shares, while Robert Pickering snapped up 7,500 shares at 617p a pop, having previously had none.
Read moreWednesday tips round-up: Carillion, Hamworthy, Heritage Oil...
5th Oct 2011 06:57
Carillion, which bought Eaga, the home insulation and green energy business, in the spring, has now raised its estimate for annualised cost savings from £9 million to £15 million, notes the Tempus column in the Times. Carillion, like its rival support services group Kier, is now seeing the promised,
Read more